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with tumor extension to the adjacent structures has been
considered equivocal. Several studies, however, have
shown improved survival of selected patients with
extrapulmonary invasion after surgery.1-4 In the staging
system for lung cancer proposed in 1986, tumors with
direct extrapulmonary extension have been subdivided
on the basis of the anatomic extent of disease and its
potential for surgical treatment.5 That is, T3 lesions
with limited, circumscribed extrapulmonary extension
are considered potentially surgically resectable, where-
as T4 tumors with extensive extrapulmonary extension
are considered unresectable.
Tumors with direct invasion of the diaphragm have
been categorized as T3 lesions in the staging system and
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are considered to be curable by resection.5 However,
only a few reports have been published concerning
results of surgical treatment of patients with those
tumors.6-9 Weksler and colleagues6 reported that tumors
invading the diaphragm were found in 0.17% of patients
with thoracotomy for non–small cell lung cancer, and
the surgical results in those 8 patients were unfavorable;
this was the first report dealing with this issue. 
In 1997, the International Union Against Cancer and
the American Joint Committee on Cancer adopted a
revised stage grouping.l0 In the new staging system, T3
N0 M0 disease is classified as stage IIB and T3 N1 M0
and T3 N2 M0 diseases as stage IIIA. Prognoses of
patients with each stage of the disease were documented
as a 38% 5-year survival for T3 N0 M0, 25% for T3 N1
M0, and 23% for T1-3 NZ M0.10  Nevertheless, the num-
ber of patients in the database with tumors involving the
diaphragm was unknown.
To obtain information on tumors with diaphragmatic
invasion and the surgical results of patients with these
diseases, we retrospectively surveyed patients with
resected lung cancer involving the diaphragm in the
institutions of the Lung Cancer Surgical Study Group
in Japan.
Patients and methods
Between January 1, 1986, and December 31, 1995, a total
of 16,771 patients underwent resection for carcinoma of the
lung at 31 institutions of the Lung Cancer Surgical Study
Group in Japan. By investigating the database, we identified
63 patients (0.38%) who had resection of T3 lung cancer
invading the diaphragm. These patients constituted the study
population. Their clinical and pathologic records were retro-
spectively analyzed, and at least a 2-year follow-up was
obtained for all living patients.
Disease stages were based on the revised TNM classifica-
tion for lung cancer.10 Histologic typing was determined
according to the World Health Organization classification.11
A resection was designated as complete when all gross dis-
ease was excised and the margins of resection were micro-
scopically clear of disease.
Survival was measured from the operation until death or
the last date of the follow-up (February 28, 1998), and the
data are reported as mean and 95% confidence intervals (CI)
for the mean. The survival curves were calculated by the
Kaplan-Meier method, and comparisons among the curves
were made by means of the log-rank test. All calculations
were performed with the use of the StatView (version 5.0;
SAS Institute Inc, Cary, NC) software package.
Results
Characteristics of the 63 patients are shown in Table I.
Among the 37 symptomatic patients (58.7%), the most
common symptoms were cough in 16 patients, hemop-
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Table I.  The characteristics of the 63 patients in this
study
Characteristic No. of patients
Sex
Male 53
Female 10
Mean age (y) 67.0 ± 7.6*
Symptoms
Asymptomatic 26
Symptomatic 37
Clinical stage
IA 4
IB 19
IIA 1
IIB 17
IIIA 19
IIIB 3
*Values are mean ± standard deviation.
Table II.  Pathologic findings of the resected tumors
All patients Patients with complete 
Variable (n = 63) resection (n = 55)
Histology
Squamous cell 38 32
Adenocarcinoma 20 19
Adenosquamous 2 2
Large cell 2 1
Mucoepidermoid 1 1
Tumor size (mm) 60.0 ± 27.1* 56.1 ± 22.5*
Combined resected organs
Diaphragm only 40 37
Diaphragm and other organs 23 18
Pathologic stage
T3 N0 M0 29 26
T3 N1 M0 12 10
T3 N2 M0 20 19
T3 NX M0 2 0
*Values are mean ± standard deviation.
Table III.  Depth of tumor invasion to the diaphragm
in all patients and in those who underwent complete
resection
Invasion of All patients Patients with complete 
the diaphragm (n = 46) resection (n = 40)
Parietal pleura 9 9
Subpleural tissue 19 17
Muscle 15 13
Peritoneum 2 1
Beyond peritoneum 1
tysis in 9, and fever and chest pain in 7 each. All patients
underwent chest computed tomographic scanning for the
evaluation of lung tumors, and magnetic resonance
imaging of the chest was performed on 6 patients. In
consequence, tumor invasion to the diaphragm was sus-
pected before the operation in only 17 (27.0%) of the
patients. The clinical stages of the tumors were therefore
diversely assessed as shown in Table I. Three patients
with clinical stage IIIB disease were believed to have
atrial invasion, a satellite nodule within the ipsilateral
primary tumor lobe, or N3 disease.
The extent of pulmonary resection consisted of a
pneumonectomy in 6 patients (9.5%), bilobectomy in
11 (17.5%), lobectomy in 43 (68.3%), and segmentec-
tomy or wedge resection in 3 (4.8%). Combined resect-
ed organs other than the diaphragm were chest wall in
10 patients, parietal pleura in 8, pericardium in 6, and
omentum in 1 patient. The diaphragm was resected en
bloc with the tumor in all patients; primary closure of
the diaphragm was performed in 60 patients and recon-
struction with a patch in 3 patients.
Table II shows pathologic findings of the tumors of
all patients and those with complete resection. The
most common histologic type was squamous cell carci-
noma and the next most common, adenocarcinoma. The
excised tumors were comparatively large, and the 6
incompletely resected tumors were more than 70 mm.
Two patients were classified as having stage T3 NX M0
disease because they had no lymph nodes sampled peri-
operatively. A complete resection was accomplished in
55 (87.3%) patients. It was performed in 37 (92.5%) of
the patients with combined resection of the diaphragm
only, but in 18 (78.3%) of the patients with excision of
the diaphragm and other neighboring structures.
Information on the depth of tumor invasion to the
diaphragm was available in 46 patients (Table III).
Regarding the degree of tumor penetration into the
diaphragm, 60.9% of all the tumors showed shallow
invasion representing parietal pleura or subpleural tis-
sue involvement and the remaining 39.1% showed deep
invasion, meaning muscle or peritoneal infiltration. In
the completely resected tumors, the rates were 65.0%
and 35.0%, respectively.
One patient (1.6%) died within 30 days of the opera-
tion. However, afterward, 5 patients died of treatment-
related complications. Adjuvant therapy was performed
in 22 (34.9%) patients. Induction chemotherapy was
carried out in only 1 patients. Postoperative therapy
was performed in 21 patients, of whom 14 patients
received chemotherapy, 3 chemoradiotherapy, and 4
radiation therapy alone. Recurrences occurred in 29 of
the patients with completely resected tumors. The site
of first relapse was defined in 19 of the patients with
recurrence; locally recurrent diseases in 4 (one at the
diaphragm), distant metastases in 13, and both local
recurrence and distant metastases in 2.
As of February 28, 1998, the median follow-up time
of all patients was 531 days with a range of 28 to 3051
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Fig 1.  Survival curves of patients who underwent surgery for lung carcinoma with diaphragmatic invasion
according to completeness of resection.
days. Fifteen patients with complete resection were
alive, and 13 of them were without recurrence. The 5-
year survival of all the patients was 19.4% (95% CI,
8.2%-30.6%). That of the 55 patients who had com-
plete resection was 22.6% (95% CI, 9.8%-35.3%),
whereas there were no 4-year survivors among the
patients with incomplete resection (P = .024) (Fig 1).
Among patients with complete resection, the 5-year
survival of patients with combined resection of the
diaphragm only was 27.6% (95% CI, 11.2%-43.9%),
but no 5-year survivor was found among patients
with excision of the diaphragm and other organs (P =
.073). A significant difference in survival according
to the stage of disease is shown in Fig 2. The 5-year
survivals of patients with stage IIB (T3 N0 M0) dis-
ease and stage IIIA (T3 N1-2 M0) disease were
28.3% (95% CI, 7.9%-48.6%) and 18.1% (95% CI,
3.1%-33.1%), respectively (P = .013). Furthermore,
the figure was 20.0% (95% CI, 0%-44.8%) for
patients with N1 disease, and there were no 5-year
survivors in the group of patients with N2 disease,
although no significant difference was found in either
group (P = .683). To estimate the impact of the depth
of diaphragmatic involvement on the prognosis, we
compared the survival curves according to the degree
of invasion (Fig 3). The 5-year survivals of patients
with shallow invasion and deep invasion were 33.0%
(95% CI, 11.1%-54.8%) and 14.3% (95% CI, 0%-
32.6%), respectively. There was a significant differ-
ence (P = .036) between the groups.
Discussion
The treatment and prognosis of patients with
non–small cell lung cancer are dependent on the stage of
the disease. Surgical resection has been shown to offer a
significant chance of cure for patients with lung carcino-
ma confined to the parenchyma. However, the surgical
candidacy of patients with tumor extension to the adja-
cent structures has elicited considerable controversy. T3
lesions such as tumors invading the chest wall, pericardi-
um, or main bronchus are generally considered potential-
ly surgically resectable for cure.1-4 Tumors with direct
invasion of the diaphragm have also been categorized to
the T3 lesions in the staging system and considered to be
curable by resection.10 Nevertheless, because lung cancer
involving the diaphragm is a rare disease, only a few
reports have been published concerning surgical treat-
ment of patients with those tumors, and those reports
contained small numbers of cases.6-9 Consequently, very
little information has been presented on the clinical fea-
tures and proper treatment of tumors with diaphragmatic
involvement.
From the present retrospective study, we have
obtained clinical data and surgical results on a number
of patients with lung cancer involving the diaphragm.
The incidence of diaphragmatic invasion encountered
at thoracotomy for resection of lung carcinoma was
low at 0.38%, and this rate was comparable with those
of previous reports (0.17%6 to 0.4%9). More than half
of the patients were symptomatic, but their symptoms
were nonspecific. Accurate diagnosis of diaphragmatic
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Fig 2.  Survival curves of patients with complete resection according to lymph node involvement.
invasion was very difficult even with chest CT, because
there are no accurate criteria for diagnosing the
diaphragmatic invasion of lung tumors. Accordingly,
the clinical stage of the patients was very diverse.
Surgical treatment consisted of en bloc resection of
the primary tumor and the involved diaphragm in all
patients. Moreover, in 23 patients (36.5%) with T3 dis-
ease, other involved structures (parietal pleura, chest
wall, and pericardium) were resected along with the
primary lesions. Tumors involving the diaphragm tend
to invade the neighboring structures. The repair method
of the diaphragm was usually primary closure irrespec-
tive of the tumor size. Since complete resection was
accomplished in 87.3% of the study population, tumors
with diaphragmatic invasion are considered resectable
lesions with an acceptable mortality only when they are
T3 N0-2 M0 tumors. The histologic types of tumors
were squamous cell carcinoma in 60.3% of the patients
and adenocarcinoma in 31.7%; these rates are compa-
rable with those of the report by Rocco and associates.9
As for the degree of tumor penetration into the
diaphragm, deeper invasion of the diaphragm may indi-
cate a more advanced tumor.
Our survival data confirmed that incomplete resec-
tion of lung cancer with diaphragmatic involvement
offered the patients no curative benefit. In patients with
complete resection, combined resection of organs other
than the diaphragm had an adverse effect on survival.
On the contrary, there is a statistically significant sur-
vival advantage for node-negative disease and shallow
tumor invasion into the diaphragm. That is, the 5-year
survival of patients with T3 N0 M0 tumors and/or shal-
low invasion was about 30%, whereas that of patients
with T3 N1-2 M0 and/or deep invasion was less than
20%. These survival results are equivalent to those of
Roccos’ series9 and are better than those of other
reports in which there were no long-term survivors.6-8
Comparing the surgical results in each TNM stage and
specific T3 organs of large series, the data of patients with
diaphragmatic invasion are worse in all stage categories
(Table IV).1-4,7-10,12,13 The T3 N0 M0 subgroup is classi-
fied as stage IIB in the revised TNM staging system, and
the 5-year survivals were reported as 33% to 52%. That
of our patients was 28.3%, which is comparable with that
of the group with stage IIIA disease. Furthermore, the
survival of 18.1% in the T3 N1-2 M0 subgroup, which is
included in stage IIIA, is lower than that (5-year survival,
23%) of the patients with T1-3 N2 M0 tumors in
Mountain’s series.10 Our survival data are comparable
with those (5-year survival: 18%-25%) of completely
resected stage IIIB diseases documented by Watanabe,14
Tsuchiya,15 and their associates. From this point of view,
tumors invading the diaphragm may be indicative of T4
disease as described by Inoue,7 Adebonojo,8 and their
colleagues, or T41 disease proposed by Grunenwald and
Le Chevalier,16 which is considered to be potentially
resectable in selected cases.
Conclusion
In selected patients with lung carcinoma and diaphrag-
matic invasion, combined resection of the lung and
diaphragm offers the prospect of cure with an acceptable
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Fig 3.  Survival curves of patients with complete resection according to the depth of diaphragmatic invasion.
mortality when a complete resection is accomplished.
Nevertheless, primary lung tumors with diaphragmatic
invasion, especially invasion of the muscle layer or deep-
er tissue, are considered to be unsuitable for T3 lesions,
because these cancers are generally technically resectable
but oncologically almost incurable diseases.
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Table IV.  Survival of patients with completely resected T3 N0-2 M0 lung cancer
Five-year survival (%) by node status
T3 organs First author Year No. of patients N0 N1 N2
All T3 organs Naruke12 1988 191 33 39
Watanabe13 1991 88 52 47 10
Mountain10 1997 142 38 25
Inoue7 1998 122 34 38 11
Adebonojo8 1999 72 47 33 15
Chest wall Shah1 1995 55 45 38 0
Pitz2 1996 83 36 23 14
Downey3 1999 175 49 27 15
Mediastinum + main bronchus Pitz4 1996 64 45 37 0
Diaphragm Rocco9 1999 15 27 0 0
Yokoi (present study) 2000 55 28 20 0
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Hirokuni Yoshimura, MD (Kitasato University, Kanagawa),
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Tetsuya Mitsudomi, MD (Aichi Cancer Center, Aichi),
Tsutomu Yasumitsu, MD (Osaka Prefectural Habikino
Hospital, Osaka), Takashi Mori, MD (National Kinki Central
Hospital, Osaka), Hirohito Tada, MD (Osaka City General
Hospital, Osaka), Hajime Maeda, MD (Toneyama National
Hospital, Osaka), Hiroshige Nakamura, MD (Tottori
University, Tottori), Hideyuki Saeki, MD (National Shikoku
Cancer Center, Ehime), Yukito Ichinose, MD (National
Kyusyu Cancer Center, Fukuoka), Tsugio Furukawa, MD
(Saga Prefectural Koseikan Hospital, Saga), and Keiichiro
Genka, MD (National Okinawa Hospital, Okinawa).
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